Use of alteplase (t-PA) for the management of thrombotic catheter dysfunction: Guidelines from a consensus conference of the National Association of Vascular Access Networks (NAVAN)

Nutrition in Clinical Practice

Volumn 15, Issue 6, 2000, Pages 265-275

  Haire, William D ^a   Herbst, Suzanne L ^b   Piperata, Jill ^c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b National Association of Vascular Access Networks   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0038070004     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/088453360001500602     Document Type: Review

References (47)

1. Food and Drug Administration. Important Drug Warning. Center for Biologies Evaluation and Research. Urokinase July, 1999.
2. Herbst SL. Options for venous access in ambulatory care: Issues in selection and management. J Infus Chemother 6:186-194, 1996.
3. Cobos E, Dixon S, Keung YK Prevention and management of central venous catheter thrombosis. Curr Opin Hematol 5:355-359, 1998-.
4. Timsit JF, Farkas JC, Boyer JM, et al. Central vein catheter-related thrombosis in intensive care patients: incidence, risk factors, and relationship with catheter-related sepsis. Chest 114: 207-213, 1998.
5. Jurado R, Ribeiro M. Possible role of systemic inflammatory reaction in vascular access thrombosis. South Med J 92:877-881, 1999.
6. Stephens LC, Haire WD, Kotulak GD. Are clinical signs accurate indicators of the cause of central venous catheter occlusion? JPEN 19:75-79, 1995.
7. Lawson M. Partial occlusion of indwelling central venous catheters. J Intraven Nurs 14:157-159, 1991.
8. Holcombe BJ, Forloines-Lynn S, Garmhausen LW. Restoring patency of long-term central venous access devices. J Intraven Nurs 15:36-41, 1992.
9. Ter Borg F, Timmer J, de Kam SS, et al. Use of sodium hydroxide solution to clear partially occluded vascular access ports. JPEN 17:289-291, 1993.
10. Pennington CR, Pithie AD. Ethanol lock in the management of catheter occlusion. JPEN 11:507-508, 1987.
11. Lindblad B. Thromboembolic complications and central venous catheters. Lancet 2:936, 1982.
12. Lowell JA, Bothe A Jr. Central venous catheter related thrombosis. Surg Oncol Clin N Am 4:479-492, 1995.
13. Moureau NL, McKinnon BT, Douglas CM. Multidisciplinary management of thrombotic catheter occlusions in vascular access devices. JVAD Summer. 22-29, 1999.
14. Stump DC, Mann KG. Mechanisms of thrombus formation and lysis. Ann Emerg Med 17:1138-1147, 1988.
15. Herbst SL, Kaplan LK, McKinnon BT. Vascular access devices: Managing occlusions and related complications in home infusion. Infusion 4-.S1-S32, 1988.
16. Tschirhart JM, Rao MK Mechanism and management of persistent withdrawal occlusions. Am Surg 54:326-328, 1988.
17. Tolar B, Gould JR. The timing and sequence of multiple device-related complications in patients with long-term indwelling Gro-shong catheters. Cancer 78:1308-1313, 1996.
18. Young C, Gould JR. The timing and sequence of multiple device-related complications in patients with indwelling subcutaneous ports. Am J Surg 174:417-421, 1997.
19. Whitman ED. Complications associated with the use of central venous access devices. Curr Probl Surg 33:309-378, 1996.
20. Wachs T. Urokinase administration in pediatric patients with occluded central venous catheters. J Intraven Nurs 13:100-102, 1990.
21. Northsea C. Using urokinase to restore patency in double lumen catheters. Am Nephrol Nurses Assoc J 21:261-264, 273, 1994.
22. Lund G, Lieberman RP, Haire WD. Central venous catheters. Semin Interven Radiol 6:162-174, 1989.
23. Hurtibise MR, Bottino JC, Lawson M, et al. Restoring patency of occluded central venous catheters. Arch Surg 1115:212-213, 1980.
24. Glynn MF, Langer B, Jeejeebhoy KN. Therapy for thrombotic occlusion of long-term intravenous alimentation catheters. JPEN 4:387-390, 1980.
25. Lawson M, Bottino JC, Hurtibise MR, et al. The use of urokinase to restore patency of occluded central venous catheters. Am J Intraven Ther Clin Nutr 9:29-32, 1982.
26. Monturo CA, Dickerson RN, Mullen JL. Efficacy of thrombolytics for occlusion of long-term catheters. JPEN 14:312-314, 1990.
27. Haire WD, Leiberman RP, Lund GB, et al. Obstructed central venous catheter: restoring function with a 12-hour infusion of low-dose urokinase. Cancer 66:2279-2285, 1990.
28. Haire WD, Lieberman RP. Thrombosed central venous catheters: restoring function with a 6-h urokinase infusion after failure of bolus urokinase. JPEN 16:129-132, 1992.
29. Whigham CJ, Greenbaum MC, Fisher RG, et al. Incidence and management of catheter occlusion in implantable arm ports: results in 391 patients. JVIR 10:767-774, 1999.
30. Haire WD, Atkinson JB, Stephens LC. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial. Thromb Haemost 72:543-547, 1994.
31. Atkinson JB, Bagnall HA, Gomperts E. Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters. JPEN 14:310-311, 1990.
32. Maloney KW, Hillery CA, Nelson TJ, Gill JC. The use of aliquoted and frozen t-PA in central venous line occlusions. Blood 1(supp): 25a. Abstract 114-1, 1999.
33. Choi M, Massicotte MP, Marzinotto V, Chan AKC, Andrew M. Use of tissue plasminogen activator to clear blocked central venous lines in pediatric patients: a prospective cohort study. Blood l(supp):25a. Abstract 96-1, 1999.
34. Food and Drug Administration. Important Drug Warning. Center for Biologies Evaluation and Research. Streptokinase December 10, 1999.
35. Froelich J, Stump DL. Recombinant tissue plasminogen activator. IN Thrombolytic Therapy for Peripheral Vascular Disease. Com-erota AJ (ed). JB Lippincott, Philadelphia, PA, 1995, pp. 103-114.
36. Lijnen HR, Collen D. Fibrinolytic agents: mechanisms of activity and pharmacology. Thromb Haemost 74:387-390, 1995.
37. Sobel BE. The language of lysis: A proposal to standardize the nomenclature. J Am Coll Cardiol 34:1226-1227, 1999.
38. Stump DC, Collen D. The fibrinolytic system: implications for thrombolytic therapy. IN Acute Coronary Care in the Thrombolytic Era. Califf RM, Mark DB, Wagner GS (eds). Year Book Medical Publishers, Chicago, IL, 1988.
39. Pennica D, Holmes WE, Kohr WJ, et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 301:214-221, 1983.
40. Collen D, Lijnen HR. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Thromb Haemost 74:167-171, 1995.
41. Smalling RW. Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator. Eur Heart J 18(suppl F):F11-G16, 1997.
42. Wooster MB, Luzier AB. Reteplase: A new thrombolytic for the treatment of acute myocardial infarction. Ann Pharmacother 33:318-324, 1999.
43. Ross AM. New plasminogen activators: A clinical review. Clin Cardiol 22:165-171, 1999.
44. Bell WR Jr. Evaluation of thrombolytic agents. Drugs 54(suppl 3):11-17, 1997.
45. Smalling RW. A fresh look at the molecular pharmacology of plasminogen activators: From theory to test tube to clinical outcomes. Am J Health Syst Pharm 54(suppl 1):S17-S22, 1997.
46. Calis KA, Cullinane AM, Home MK. Bioactivity of cryopreserved alteplase solutions. Am J Health Syst Pharm 56:2056-2057, 1999.
47. Data on file. Genentech, Inc. South San Francisco, CA.